Working… Menu
Trial record 34 of 101 for:    FEC

6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer Patients (NNBC3-Europe)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01222052
Recruitment Status : Unknown
Verified June 2017 by Christoph Thomssen, Martin-Luther-Universität Halle-Wittenberg.
Recruitment status was:  Active, not recruiting
First Posted : October 18, 2010
Last Update Posted : June 26, 2017
German Breast Group
Information provided by (Responsible Party):
Christoph Thomssen, Martin-Luther-Universität Halle-Wittenberg